-
Mashup Score: 2(1) Post | LinkedIn - 1 year(s) ago
Univ.-Prof.Dr. Ralph Stephan von Bardeleben Univ.-Professor Interv. Klappentherapie, Head Heart Valve Center, Editor in Chief Echocardiography, Full Professor Interventional Heart Valve Tx Cardiology JGU University of Mainz, ACHD EMAH View full profile
Source: www.linkedin.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 3Ralph Stephan von Bardeleben on LinkedIn: #TTVR #Evoque #Mainz - 2 year(s) ago
#TTVR #Evoque The first human implant outside the first three in Canada was performed as EU compassionate use in #Mainz by Ralph Stephan von Bardeleben…
Source: www.linkedin.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 2AATS 101st Annual Meeting: Log in to the site - 3 year(s) ago
AATS 101st Annual Meeting Skip to create new account …
Source: annualmeeting.aats.orgCategories: Cardiac Surgery, Latest HeadlinesTweet
-
Mashup Score: 1Edwards Lifesciences portfolio in action - Innovation in mitral and tricuspid repair & replacement - 3 year(s) ago
Presented by: Stephan Baldus, Martin Arnold, Jorg Hausleiter, Philipp Lurz during PCR Valves e-Course 2020.00:08 Session objectives – S. Baldus02:56 PASCAL r…
Source: YouTubeCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Pediheart Podcast #131: Adverse Events, Radiation And Reintervention After Transcatheter Pulmonary Valve Replacement - 4 year(s) ago
This week we review a recent work from the C3P0 registry on trans-catheter pulmonary valves. How common were adverse events encountered in this ‘real world’ assessment? How does this value compare with surgical pulmonary valve replacement? What factors are associated with higher doses of radiation in this procedure? We speak with Dr. Barry Love, Director of the Congenital Catheterization…
Source: SpreakerCategories: Cardiologists, Latest HeadlinesTweet
#PCRLV 2022 opening live cases from #Copenhagen with Lars Sondergaard and #Mainz with @vonBardelebenRS and an #Edwards #Evoque #Tricuspid #replacement #TTVR transvenous transfemoral onging #TRISCEND II trial https://t.co/R4j0EM0woi https://t.co/veDU2YJE6w